These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


100 related items for PubMed ID: 9506865

  • 1. Effects of short-term treatment with insulin-like growth factor-I and growth hormone on serum lipoprotein (a) in growth hormone-deficient adults.
    Bianda T, Schmid C.
    Eur J Endocrinol; 1998 Feb; 138(2):189-90. PubMed ID: 9506865
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Sääf M, Baylink DJ, Mohan S.
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [Abstract] [Full Text] [Related]

  • 7. Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy.
    Giavoli C, Porretti S, Ronchi CL, Cappiello V, Ferrante E, Orsi E, Arosio M, Beck-Peccoz P.
    Metabolism; 2004 Jun; 53(6):740-3. PubMed ID: 15164321
    [Abstract] [Full Text] [Related]

  • 8. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial.
    Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N, Klibanski A.
    Ann Intern Med; 2000 Jul 18; 133(2):111-22. PubMed ID: 10896637
    [Abstract] [Full Text] [Related]

  • 9. Different effects of continuous and intermittent patterns of growth hormone administration on lipoprotein levels in growth hormone-deficient patients.
    Laursen T, Lemming L, Jørgensen JO, Klausen IC, Christiansen JS.
    Horm Res; 1998 Jul 18; 50(5):284-91. PubMed ID: 9873197
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults.
    Yuen K, Cook D, Ong K, Chatelain P, Fryklund L, Gluckman P, Ranke MB, Rosenfeld R, Dunger D.
    Clin Endocrinol (Oxf); 2002 Sep 18; 57(3):333-41. PubMed ID: 12201825
    [Abstract] [Full Text] [Related]

  • 12. Treatment of growth hormone deficiency syndrome in adults.
    De Feo P, Lucidi P, Santeusanio F.
    Diabetes Nutr Metab; 1999 Oct 18; 12(5):336-9. PubMed ID: 10741348
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy of long-term growth hormone therapy in short non-growth hormone-deficient children.
    Schena L, Meazza C, Pagani S, Paganelli V, Bozzola E, Tinelli C, Buzi F, Bozzola M.
    J Pediatr Endocrinol Metab; 2017 Feb 01; 30(2):197-201. PubMed ID: 28099132
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effect of growth hormone replacement therapy for up to 12 months on lipoprotein composition and lipoprotein(a) in growth hormone-deficient adults.
    Webster JM, Stewart M, al-Maskari M, Osman I, Kendall-Taylor P, Mitcheson J, Laker MF.
    Atherosclerosis; 1997 Aug 01; 133(1):115-21. PubMed ID: 9258415
    [Abstract] [Full Text] [Related]

  • 16. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults.
    Pfeifer M, Verhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN.
    J Clin Endocrinol Metab; 1999 Feb 01; 84(2):453-7. PubMed ID: 10022400
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.
    Christopher M, Hew FL, Oakley M, Rantzau C, Alford F.
    J Clin Endocrinol Metab; 1998 May 01; 83(5):1668-81. PubMed ID: 9589675
    [Abstract] [Full Text] [Related]

  • 19. Growth hormone.
    Matsuno A.
    J Neurosurg; 2007 May 01; 106(5):940; author reply 940-1. PubMed ID: 17542549
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 5.